<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392271</url>
  </required_header>
  <id_info>
    <org_study_id>17243</org_study_id>
    <secondary_id>I9X-MC-MTAD</secondary_id>
    <nct_id>NCT04392271</nct_id>
  </id_info>
  <brief_title>A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants</brief_title>
  <official_title>Assessment of Brain O-GlcNAcase (OGA) Enzyme Occupancy After Multiple Oral Doses of LY3372689 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]LY3316612 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study&#xD;
      will be conducted in healthy participants and will last up to about 10 weeks. Screening must&#xD;
      be completed within four weeks prior to enrollment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 6, 2020</start_date>
  <completion_date type="Actual">October 14, 2020</completion_date>
  <primary_completion_date type="Actual">October 14, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent O-GlcNAcase (OGA) Enzyme Occupancy (EO)</measure>
    <time_frame>Approximately 2 to 96 hours following the first dose</time_frame>
    <description>Percent OGA EO</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent OGA EO</measure>
    <time_frame>Approximately 2 to 96 hours following the last dose</time_frame>
    <description>Percent OGA EO</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve During the Dosing Interval (AUC[0-tau]) of LY3372689</measure>
    <time_frame>Baseline through 24 hours</time_frame>
    <description>PK: AUC(0-tau) of LY3372689</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of LY3372689</measure>
    <time_frame>Baseline through 24 hours</time_frame>
    <description>PK: Cmax of LY3372689</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3372689 + [18F]LSN3316612</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3372689 administered orally followed by [18F]LSN3316612 PET tracer administered intravenously (IV) approximately 24 hours later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3372689</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3372689 + [18F]LSN3316612</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>[18F]LSN3316612</intervention_name>
    <description>Administered intravenously (IV).</description>
    <arm_group_label>LY3372689 + [18F]LSN3316612</arm_group_label>
    <other_name>[18F]MNI-1068</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overtly healthy males or females who do not have child-bearing potential&#xD;
&#xD;
          -  Have a body mass index (BMI) of greater than (&gt;)18 to less than or equal to (≤32)&#xD;
             kilograms per square meter (kg/m²), inclusive, at screening&#xD;
&#xD;
          -  Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood&#xD;
             and urine laboratory test results that are acceptable for the study&#xD;
&#xD;
          -  Have venous access sufficient to allow for blood sampling&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history of head injury or contraindications to undergoing magnetic resonance&#xD;
             imaging (MRI) examination&#xD;
&#xD;
          -  Are currently participating in or completed a clinical trial within the last 30 days&#xD;
             or any other type of medical research judged to be incompatible with this study&#xD;
&#xD;
          -  Have previously participated or withdrawn from this study&#xD;
&#xD;
          -  Have had prior participation in other research protocols or clinical care in the&#xD;
             preceding year in addition to the radiation exposure expected from participation in&#xD;
             this clinical study, such that radiation exposure exceeds the effective dose of 50&#xD;
             milliSievert (mSv), which would be above the acceptable annual limit established by&#xD;
             the US Federal Guidelines&#xD;
&#xD;
          -  Are current smokers or have used tobacco or nicotine-containing products as determined&#xD;
             by the cotinine test&#xD;
&#xD;
          -  Have or used to have health problems or laboratory test results or ECG readings that,&#xD;
             in the opinion of the doctor, could make it unsafe to participate or could interfere&#xD;
             with understanding the results of the study&#xD;
&#xD;
          -  Participate in regular vigorous exercise&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

